M Esteller

Summary

Country: Spain

Publications

  1. pmc Epigenetics provides a new generation of oncogenes and tumour-suppressor genes
    M Esteller
    Cancer Epigenetics Laboratory, 3rd Floor, Molecular Pathology Programme, Spanish National Cancer Centre CNIO, Melchor Fernandez Almagro 3, 28029 Madrid, Spain
    Br J Cancer 94:179-83. 2006
  2. ncbi A truncating mutation of HDAC2 in human cancers confers resistance to histone deacetylase inhibition
    Santiago Ropero
    Cancer Epigenetics Laboratory, Spanish National Cancer Centre CNIO, 28029 Madrid, Spain
    Nat Genet 38:566-9. 2006
  3. pmc A microRNA DNA methylation signature for human cancer metastasis
    Amaia Lujambio
    Cancer Epigenetics Laboratory, Spanish National Cancer Research Center, Melchor Fernandez Almagro 3, 28029 Madrid, Spain
    Proc Natl Acad Sci U S A 105:13556-61. 2008
  4. pmc The loss of NKX3.1 expression in testicular--and prostate--cancers is not caused by promoter hypermethylation
    Guro E Lind
    Department of Genetics, Institute for Cancer Research, The Norwegian Radium Hospital, 0310 Oslo, Norway
    Mol Cancer 4:8. 2005
  5. pmc A CpG island hypermethylation profile of primary colorectal carcinomas and colon cancer cell lines
    Guro E Lind
    Department of Genetics, Institute for Cancer Research, The Norwegian Radium Hospital, 0310 Oslo, Norway
    Mol Cancer 3:28. 2004
  6. doi Epigenetics in cancer
    Manel Esteller
    Cancer Epigenetics Laboratory, Spanish National Cancer Research Center, Madrid, Spain
    N Engl J Med 358:1148-59. 2008
  7. ncbi Profiling aberrant DNA methylation in hematologic neoplasms: a view from the tip of the iceberg
    Manel Esteller
    Cancer Epigenetics Laboratory, Spanish National Cancer Center CNIO, Melchor Fernandez Almagro 3, 28029 Madrid, Spain
    Clin Immunol 109:80-8. 2003
  8. ncbi Epigenetic gene silencing in cancer: the DNA hypermethylome
    Manel Esteller
    Cancer Epigenetics Laboratory, Spanish National Cancer Centre CNIO, Melchor Fernandez Almagro 3, 28029 Madrid, Spain
    Hum Mol Genet 16:R50-9. 2007
  9. ncbi Aberrant DNA methylation as a cancer-inducing mechanism
    Manel Esteller
    Cancer Epigenetics Laboratory, Spanish National Cancer Center CNIO, Melchor Fernandez Almagro 3, 28029 Madrid, Spain
    Annu Rev Pharmacol Toxicol 45:629-56. 2005
  10. ncbi DNA methylation and cancer therapy: new developments and expectations
    Manel Esteller
    Cancer Epigenetics Laboratory, Spanish National Cancer Centre CNIO Madrid, Spain
    Curr Opin Oncol 17:55-60. 2005

Detail Information

Publications88

  1. pmc Epigenetics provides a new generation of oncogenes and tumour-suppressor genes
    M Esteller
    Cancer Epigenetics Laboratory, 3rd Floor, Molecular Pathology Programme, Spanish National Cancer Centre CNIO, Melchor Fernandez Almagro 3, 28029 Madrid, Spain
    Br J Cancer 94:179-83. 2006
    ....
  2. ncbi A truncating mutation of HDAC2 in human cancers confers resistance to histone deacetylase inhibition
    Santiago Ropero
    Cancer Epigenetics Laboratory, Spanish National Cancer Centre CNIO, 28029 Madrid, Spain
    Nat Genet 38:566-9. 2006
    ..As such drugs may serve as therapeutic agents for cancer, our findings support the use of HDAC2 mutational status in future pharmacogenetic treatment of these individuals...
  3. pmc A microRNA DNA methylation signature for human cancer metastasis
    Amaia Lujambio
    Cancer Epigenetics Laboratory, Spanish National Cancer Research Center, Melchor Fernandez Almagro 3, 28029 Madrid, Spain
    Proc Natl Acad Sci U S A 105:13556-61. 2008
    ..Our findings indicate that DNA methylation-associated silencing of tumor suppressor miRNAs contributes to the development of human cancer metastasis...
  4. pmc The loss of NKX3.1 expression in testicular--and prostate--cancers is not caused by promoter hypermethylation
    Guro E Lind
    Department of Genetics, Institute for Cancer Research, The Norwegian Radium Hospital, 0310 Oslo, Norway
    Mol Cancer 4:8. 2005
    ....
  5. pmc A CpG island hypermethylation profile of primary colorectal carcinomas and colon cancer cell lines
    Guro E Lind
    Department of Genetics, Institute for Cancer Research, The Norwegian Radium Hospital, 0310 Oslo, Norway
    Mol Cancer 3:28. 2004
    ..We compared the DNA methylation profiles of the cell lines with those of the primary tumors. Finally, we examined if the epigenetic changes were associated with known genetic markers and/or clinicopathological variables...
  6. doi Epigenetics in cancer
    Manel Esteller
    Cancer Epigenetics Laboratory, Spanish National Cancer Research Center, Madrid, Spain
    N Engl J Med 358:1148-59. 2008
  7. ncbi Profiling aberrant DNA methylation in hematologic neoplasms: a view from the tip of the iceberg
    Manel Esteller
    Cancer Epigenetics Laboratory, Spanish National Cancer Center CNIO, Melchor Fernandez Almagro 3, 28029 Madrid, Spain
    Clin Immunol 109:80-8. 2003
    ..Furthermore, promising studies using DNA demethylating agents and histone deacetylase inhibitors are underway to awake these dormant tumor-suppressor genes for a better treatment of the patient with a hematologic malignancy...
  8. ncbi Epigenetic gene silencing in cancer: the DNA hypermethylome
    Manel Esteller
    Cancer Epigenetics Laboratory, Spanish National Cancer Centre CNIO, Melchor Fernandez Almagro 3, 28029 Madrid, Spain
    Hum Mol Genet 16:R50-9. 2007
    ..In the very near future, the synergy of candidate gene approaches and large-scale epigenomic technologies, such as methyl-DIP, will yield the complete DNA hypermethylome of cancer cells...
  9. ncbi Aberrant DNA methylation as a cancer-inducing mechanism
    Manel Esteller
    Cancer Epigenetics Laboratory, Spanish National Cancer Center CNIO, Melchor Fernandez Almagro 3, 28029 Madrid, Spain
    Annu Rev Pharmacol Toxicol 45:629-56. 2005
    ..Finally, we must expect the development of new and more specific DNA demethylating agents that awake these methyl-dormant tumor suppressor genes and prove their therapeutic values. The expectations are high...
  10. ncbi DNA methylation and cancer therapy: new developments and expectations
    Manel Esteller
    Cancer Epigenetics Laboratory, Spanish National Cancer Centre CNIO Madrid, Spain
    Curr Opin Oncol 17:55-60. 2005
    ..These sites, among others, are the targets of DNA-demethylating agents, the promising chemotherapeutic drugs that are the focus of this article...
  11. ncbi Dormant hypermethylated tumour suppressor genes: questions and answers
    Manel Esteller
    Cancer Epigenetics Laboratory, Molecular Pathology Programme, Spanish National Cancer Centre CNIO, Madrid, Spain
    J Pathol 205:172-80. 2005
    ....
  12. ncbi The necessity of a human epigenome project
    Manel Esteller
    Cancer Epigenetics Laboratory, Spanish National Cancer Centre CNIO, Melchor Fernandez Almagro 3, 28029 Madrid, Spain
    Carcinogenesis 27:1121-5. 2006
    ..We need to make an ambitious step to understand the DNA methylation and histone changes underlying tumorigenesis. The launching of an International Human Epigenome Project should be the response to this necessity...
  13. ncbi Generating mutations but providing chemosensitivity: the role of O6-methylguanine DNA methyltransferase in human cancer
    Manel Esteller
    Cancer Epigenetics Laboratory, Molecular Pathology Program, Spanish National Cancer Center CNIO, Melchor Fernandez Almagro 3, Madrid 28029, Spain
    Oncogene 23:1-8. 2004
    ..These recent results underscore the importance of MGMT in basic and translational cancer research...
  14. pmc How epigenetics integrates nuclear functions. Workshop on epigenetics and chromatin: transcriptional regulation and beyond
    Manel Esteller
    Cancer Epigenetics Laboratory, Spanish National Cancer Centre CNIO, Melchor Fernandez Almagro 3, 28029 Madrid, Spain
    EMBO Rep 6:624-8. 2005
  15. ncbi Cancer epigenomics: DNA methylomes and histone-modification maps
    Manel Esteller
    Cancer Epigenetics Laboratory, Spanish National Cancer Centre CNIO, Melchor Fernandez Almagro 3, 28029 Madrid, Spain
    Nat Rev Genet 8:286-98. 2007
    ..It is time to 'upgrade' cancer epigenetics research and put together an ambitious plan to tackle the many unanswered questions in this field using epigenomics approaches...
  16. ncbi Relevance of DNA methylation in the management of cancer
    Manel Esteller
    Cancer Epigenetics Laboratory at the Spanish National Cancer Centre CNiO, Madrid, Spain
    Lancet Oncol 4:351-8. 2003
    ..Finally, dormant tumour suppressor genes can be reactivated by DNA demethylating drugs, with the aim of reversing the neoplastic phenotype. These are new avenues worth exploring in the fight against cancer...
  17. pmc Epigenetic control of nuclear architecture
    J Espada
    Cancer Epigenetics Laboratory, Spanish National Cancer Centre CNIO, Melchor Fernandez Almagro 3, 28029, Madrid, Spain
    Cell Mol Life Sci 64:449-57. 2007
    ..Here we briefly summarize present concepts of nuclear architecture and current data supporting a link between DNA methylation and the maintenance of large-scale nuclear organization...
  18. doi Transforming pathways unleashed by a HDAC2 mutation in human cancer
    S Ropero
    Cancer Epigenetics Laboratory, Spanish National Cancer Centre CNIO, Madrid, Spain
    Oncogene 27:4008-12. 2008
    ..These results suggest a role for HDAC2 mutations in human tumorigenesis through the derepression of key genes from multiple cellular transformation pathways...
  19. ncbi Transcriptional targets of the chromatin-remodelling factor SMARCA4/BRG1 in lung cancer cells
    Pedro P Medina
    Lung Cancer Group, Molecular Pathology Programme, Spanish National Cancer Centre, C Melchior Fernandez Almagro 3, 28029 Madrid, Spain
    Hum Mol Genet 14:973-82. 2005
    ....
  20. ncbi Methyl-CpG-binding proteins in cancer: blaming the DNA methylation messenger
    Esteban Ballestar
    Cancer Epigenetics Laboratory, Spanish National Cancer Centre, Madrid, Spain
    Biochem Cell Biol 83:374-84. 2005
    ..The latter is a member of this family of proteins and appears to play a role in reducing mutations at 5-methylcytosine. This review examines the contribution of methyl-CpG-binding proteins in the epigenetic pathway of cancer...
  21. doi Unmasking of epigenetically silenced candidate tumor suppressor genes by removal of methyl-CpG-binding domain proteins
    L Lopez-Serra
    Cancer Epigenetics Laboratory, Spanish National Cancer Research Centre CNIO, Madrid, Spain
    Oncogene 27:3556-66. 2008
    ..Our data support a fundamental role for MBD proteins in the direct maintenance of transcriptional repression of tumor suppressors and identify new candidate genes for epigenetic disruption in cancer cells...
  22. doi Epigenetic regulation of telomeres in human cancer
    E Vera
    Telomeres and Telomerase Group, Molecular Oncology Program, Spanish National Cancer Center CNIO, Madrid, Spain
    Oncogene 27:6817-33. 2008
    ..All together, these findings suggest that tumor telomere length and integrity can be influenced by the epigenetic status of cancer cells...
  23. ncbi Mutator pathways unleashed by epigenetic silencing in human cancer
    Filipe V Jacinto
    Cancer Epigenetics Laboratory, Molecular Pathology Programme, Spanish National Cancer Centre CNIO, Madrid, Spain
    Mutagenesis 22:247-53. 2007
    ....
  24. pmc Methyl-CpG binding proteins identify novel sites of epigenetic inactivation in human cancer
    Esteban Ballestar
    Epigenetics Laboratory, Molecular Pathology Programme, Spanish National Cancer Centre CNIO, Melchor Fernandez Almagro 3, 28029 Madrid, Spain
    EMBO J 22:6335-45. 2003
    ..Our results support an essential role for MBDs in gene silencing and, when combined with genomic strategies, their potential to 'catch' new hypermethylated genes in cancer...
  25. ncbi Genetic unmasking of epigenetically silenced tumor suppressor genes in colon cancer cells deficient in DNA methyltransferases
    Maria F Paz
    Cancer Epigenetics Laboratory, Spanish National Cancer Centre CNIO, Melchor Fernandez Almagro 3, 28029 Madrid, Spain
    Hum Mol Genet 12:2209-19. 2003
    ..Thus, our results demonstrate the role of DNMT1 and DNMT3b in CpG island methylation associated silencing and the usefulness of genetic disruption strategies in searching for new hypermethylated loci...
  26. ncbi DNA methylation and histone modifications in patients with cancer: potential prognostic and therapeutic targets
    Michel Herranz
    Cancer Epigenetic Laboratory, Molecular Pathology Program, Spanish National Cancer Centre, Madrid, Spain
    Methods Mol Biol 361:25-62. 2007
    ..Aberrant patterns of epigenetic modifications will be, in a near future, crucial parameters in cancer diagnosis and prognosis...
  27. ncbi Epigenetic loss of the familial tumor-suppressor gene exostosin-1 (EXT1) disrupts heparan sulfate synthesis in cancer cells
    Santiago Ropero
    Cancer Epigenetics Laboratory, Spanish National Cancer Centre, Madrid, Spain
    Hum Mol Genet 13:2753-65. 2004
    ..These findings highlight the importance of EXT1 epigenetic inactivation, leading to an abrogation of HS biosynthesis, in the processes of tumor onset and progression...
  28. ncbi Clustering of gene hypermethylation associated with clinical risk groups in neuroblastoma
    Miguel Alaminos
    Cancer Epigenetics Laboratory, Spanish National Cancer Centre CNIO, Melchor Fernandez Almagro 3, 28029 Madrid, Spain
    J Natl Cancer Inst 96:1208-19. 2004
    ..Transcriptional silencing of tumor suppressor genes mediated by hypermethylation of promoter CpG islands is a hallmark of human tumors. We addressed the clinical relevance of promoter hypermethylation in neuroblastoma...
  29. ncbi A mouse skin multistage carcinogenesis model reflects the aberrant DNA methylation patterns of human tumors
    Mario F Fraga
    Cancer Epigenetics Laboratory, Molecular Pathology Program, Spanish National Cancer Centre, Madrid, Spain
    Cancer Res 64:5527-34. 2004
    ....
  30. ncbi The impact of chromatin in human cancer: linking DNA methylation to gene silencing
    Esteban Ballestar
    Cancer Epigenetics Laboratory, Molecular Pathology Program, Centro Nacional de Investigaciones Oncologicas, 28029 Madrid, Spain
    Carcinogenesis 23:1103-9. 2002
    ..In this review we present the models of how repressor complexes may modify chromatin structure and mediate silencing of tumour suppressor and DNA repair genes...
  31. ncbi Epigenetic inactivation of the Wnt antagonist DICKKOPF-1 (DKK-1) gene in human colorectal cancer
    O Aguilera
    Instituto de Investigaciones Biomédicas Alberto Sols and Departamento de Bioquímica, Facultad de Medicina, Consejo Superior de Investigaciones Cientificas Universidad Autonoma de Madrid, Madrid, Spain
    Oncogene 25:4116-21. 2006
    ....
  32. doi Epigenetic inactivation of the ERK inhibitor Spry2 in B-cell diffuse lymphomas
    A Sanchez
    1Unidad de Biología Celular, Centro Nacional de Microbiologia, Instituto de Salud Carlos III, Madrid, Spain
    Oncogene 27:4969-72. 2008
    ..Finally, we detected that hSpry2 promoter hypermethylation was associated with a significant decrease in the 5-year survival rate. These data suggest that hSpry2 could be important in lymphoid malignancies...
  33. pmc Proteins that bind methylated DNA and human cancer: reading the wrong words
    L Lopez-Serra
    Cancer Epigenetics Group, Spanish National Cancer Research Centre CNIO, Melchor Fernandez Almagro 3, Madrid 28029, Spain
    Br J Cancer 98:1881-5. 2008
    ..The generation of novel aberrantly hypermethylated regions during cancer development and progression makes MBD proteins interesting targets for their biological and clinical implications...
  34. ncbi CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future
    Manel Esteller
    Cancer Epigenetics Laboratory, Molecular Pathology Program, Centro Nacional de Investigaciones Oncologicas, 28029 Madrid, Spain
    Oncogene 21:5427-40. 2002
    ..Basic and translational will both be needed in the near future to fully understand the mechanisms, roles and uses of CpG island hypermethylation in human cancer. The expectations are high...
  35. ncbi CpG island hypermethylation of tumor suppressor microRNAs in human cancer
    Amaia Lujambio
    Cancer Epigenetics Laboratory, Spanish National Cancer Centre, Madrid, Spain
    Cell Cycle 6:1455-9. 2007
    ..In the coming years we will come to realize more fully the relevance of this expected encounter between two forces-epigenetics and microRNAs-that are currently at the forefront of biology...
  36. ncbi Germ-line variants in methyl-group metabolism genes and susceptibility to DNA methylation in normal tissues and human primary tumors
    Maria F Paz
    Cancer Epigenetics Laboratory, Molecular Pathology Program, Spanish National Cancer Research Center CNIO, 28029 Madrid, Spain
    Cancer Res 62:4519-24. 2002
    ..029). The existence of these associations may provide another example of the interplay between genetic and epigenetic factors in the cancer cell...
  37. ncbi A profile of methyl-CpG binding domain protein occupancy of hypermethylated promoter CpG islands of tumor suppressor genes in human cancer
    Lidia Lopez-Serra
    Cancer Epigenetics Laboratory, Spanish National Cancer Centre, Madrid, Spain
    Cancer Res 66:8342-6. 2006
    ..Our results indicate that MBDs have a great affinity in vivo for binding hypermethylated promoter CpG islands of tumor suppressor genes, with a specific profile of MBD occupancy that it is gene and tumor type specific...
  38. ncbi Histone deacetylase inhibitors: understanding a new wave of anticancer agents
    Ana Villar-Garea
    Cancer Epigenetics Laboratory, Spanish National Cancer Centre, Madrid, Spain
    Int J Cancer 112:171-8. 2004
    ..Our current data indicate that the use of HDAC inhibitors, probably in association with classical chemotherapy drugs or in combination with DNA-demethylating agents, could be promising for cancer patients...
  39. pmc Epigenetic inactivation of the premature aging Werner syndrome gene in human cancer
    Ruben Agrelo
    Cancer Epigenetics Laboratory, Spanish National Cancer Centre, Melchor Fernandez Almagro 3, 28029 Madrid, Spain
    Proc Natl Acad Sci U S A 103:8822-7. 2006
    ..These findings highlight the importance of WRN epigenetic inactivation in human cancer, leading to enhanced chromosomal instability and hypersensitivity to chemotherapeutic drugs...
  40. doi Salermide, a Sirtuin inhibitor with a strong cancer-specific proapoptotic effect
    E Lara
    Cancer Epigenetics Laboratory, Spanish National Cancer Research Centre CNIO, Madrid, Spain
    Oncogene 28:781-91. 2009
    ..Taken together, our results underline Salermide's promise as an anticancer drug and provide evidence for the molecular mechanism through which Sirt1 is involved in human tumorigenesis...
  41. ncbi New therapeutic targets in cancer: the epigenetic connection
    Michel Herranz
    Cancer Epigenetics Laboratory, Molecular Pathology Program, Spanish National Cancer Centre CNIO, Madrid, Spain
    Clin Transl Oncol 8:242-9. 2006
    ..Aberrant patterns of epigenetic modifications will be, in a near future, crucial parameters in cancer diagnosis, prognosis and therapy...
  42. ncbi The epigenetic breakdown of cancer cells: from DNA methylation to histone modifications
    Esteban Ballestar
    Cancer Epigenetics Laboratory, Spanish National Cancer Centre CNIO, Melchor Fernandez Almagro 3, 28029 Madrid, Spain
    Prog Mol Subcell Biol 38:169-81. 2005
    ..The identification of these connections has contributed not only to understanding how epigenetic deregulation occurs in cancer but also to developing novel therapies that can reverse epigenetic defects in cancer cells...
  43. pmc Epigenetic disruption of ribosomal RNA genes and nucleolar architecture in DNA methyltransferase 1 (Dnmt1) deficient cells
    Jesus Espada
    Cancer Epigenetics Laboratory, Spanish National Cancer Centre CNIO, Madrid, Spain
    Nucleic Acids Res 35:2191-8. 2007
    ..These findings suggest a role for Dnmt1 as an epigenetic caretaker for the maintenance of nucleolar structure...
  44. ncbi Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer
    Mario F Fraga
    Cancer Epigenetics Laboratory, Molecular Pathology Program, Spanish National Cancer Center, Melchor Fernandez Almagro 3, 28029 Madrid, Spain
    Nat Genet 37:391-400. 2005
    ..Our data suggest that the global loss of monoacetylation and trimethylation of histone H4 is a common hallmark of human tumor cells...
  45. ncbi Cancer epigenetics: DNA methylation and chromatin alterations in human cancer
    Manel Esteller
    Cancer Epigenetics Laboratory, Spanish National Cancer Center CNIO, Melchor Fernandez Almagro 3, 28029 Madrid, Spain
    Adv Exp Med Biol 532:39-49. 2003
    ..The eruption of new technologies for the careful study of the DNA methylation patterns, and their genetic partners in accomplishing gene silencing, it may also provide us with new drugs for the epigenetic treatment of human tumors...
  46. ncbi Combinatorial effects of splice variants modulate function of Aiolos
    Rosalia Caballero
    Cancer Epigenetics Laboratory, Molecular Pathology Programme, Spanish National Cancer Research Centre CNIO, Melchor Fernandez Almagro 3, 28029 Madrid, Spain
    J Cell Sci 120:2619-30. 2007
    ..These data support the general principle that the function of an individual protein is modulated through alternative splicing, and highlight a number of potential implications for Aiolos in normal and aberrant lymphocyte function...
  47. ncbi Human DNA methyltransferase 1 is required for maintenance of the histone H3 modification pattern
    Jesus Espada
    Epigenetics Laboratory, Spanish National Cancer Centre CNIO, Melchor Fernandez Almagro 3, 28029 Madrid, Spain
    J Biol Chem 279:37175-84. 2004
    ..Our data indicate that DNMT1 activity, via maintenance of the appropriate histone H3 modifications, contributes to the preservation of the correct organization of large heterochromatic regions...
  48. doi Epigenetic inactivation of the Groucho homologue gene TLE1 in hematologic malignancies
    Mario F Fraga
    Cancer Epigenetics Laboratory, Spanish National Cancer Research Centre, Madrid, Spain
    Cancer Res 68:4116-22. 2008
    ..These data suggest that TLE1 epigenetic inactivation contributes to the development of hematologic malignancies by disrupting critical differentiation and growth-suppressing pathways...
  49. ncbi MGMT hypermethylation: a prognostic foe, a predictive friend
    Filipe V Jacinto
    Cancer Epigenetics Laboratory, Molecular Pathology Programme, Spanish National Cancer Centre CNIO, Madrid, Spain
    DNA Repair (Amst) 6:1155-60. 2007
    ..These findings underline the importance of MGMT promoter hypermethylation in basic and translational cancer research...
  50. ncbi The Wnt antagonist DICKKOPF-1 gene is induced by 1alpha,25-dihydroxyvitamin D3 associated to the differentiation of human colon cancer cells
    Oscar Aguilera
    Instituto de Investigaciones Biomedicas Alberto Sols, Facultad de Medicina, Consejo Superior de Investigaciones Cientificas Universidad Autonoma de Madrid, Arturo Duperier, 4, 28029 Madrid, Spain
    Carcinogenesis 28:1877-84. 2007
    ..DKK-1 gene induction constitutes a novel mechanism of inhibition of Wnt signalling and antitumour action by 1,25(OH)2D3...
  51. pmc The affinity of different MBD proteins for a specific methylated locus depends on their intrinsic binding properties
    Mario F Fraga
    Cancer Epigenetics Laboratory, Molecular Pathology Program, Spanish National Cancer Center CNIO, C Melchor Fernández Almagro, no 3, E 28029, Madrid, Spain
    Nucleic Acids Res 31:1765-74. 2003
    ..Interestingly, the binding affinity of specific MBD proteins for methylated DNA fragments from naturally occurring sequences are affected by local methyl-CpG spacing...
  52. doi Epigenetic gene regulation in cancer
    Esteban Ballestar
    Cancer Epigenetics Group, Molecular Pathology Programme, Spanish National Cancer Centre CNIO, 28029 Madrid, Spain
    Adv Genet 61:247-67. 2008
    ..In addition, because epigenetic changes are reversible, enzymes involved in their maintenance stand as targets for a variety of compounds for therapy...
  53. doi Quantification of global DNA methylation by capillary electrophoresis and mass spectrometry
    Maria Berdasco
    Epigenetics Group, Molecular Pathology Program, Spanish National Cancer Center C N I O, Madrid, Spain
    Methods Mol Biol 507:23-34. 2009
    ....
  54. ncbi Cross-talk between aging and cancer: the epigenetic language
    Mario F Fraga
    Epigenetics Laboratory, Spanish National Cancer Centre CNIO, 28029 Madrid, Spain
    Ann N Y Acad Sci 1100:60-74. 2007
    ..We discuss the biological significance of both groups of epigenetic modifications in terms of their relative contribution to ontogenic development, senescence, and cell proliferation...
  55. doi A TARBP2 mutation in human cancer impairs microRNA processing and DICER1 function
    Sonia A Melo
    Cancer Epigenetics Laboratory, Spanish National Cancer Research Centre CNIO, 28029 Madrid, Spain
    Nat Genet 41:365-70. 2009
    ..Most important, the TRBP impairment is associated with a destabilization of the DICER1 protein. These results provide, for a subset of human tumors, an explanation for the observed defects in the expression of mature miRNAs...
  56. pmc The RNA-binding protein HuR regulates DNA methylation through stabilization of DNMT3b mRNA
    Isabel Lopez de Silanes
    Cancer Epigenetics Laboratory, Molecular Pathology Program, Spanish National Cancer Research Centre CNIO, 28029 Madrid, Spain
    Nucleic Acids Res 37:2658-71. 2009
    ....
  57. ncbi Aberrant regulation of messenger RNA 3'-untranslated region in human cancer
    Isabel Lopez de Silanes
    Cancer Epigenetics Laboratory, Spanish National Cancer Centre, Madrid, Spain
    Cell Oncol 29:1-17. 2007
    ..A thorough understanding of these alterations and their impact upon 3'UTR-directed posttranscriptional gene regulation will uncover promising new targets for therapeutic intervention...
  58. pmc Cancer genes hypermethylated in human embryonic stem cells
    Vincenzo Calvanese
    Cancer Epigenetics Group, Spanish National Cancer Research Centre, CNIO, Madrid, Spain
    PLoS ONE 3:e3294. 2008
    ....
  59. ncbi The epigenetic face of systemic lupus erythematosus
    Esteban Ballestar
    Cancer Epigenetics Laboratory, Molecular Pathology Programme, Spanish National Cancer Centre CNIO, Madrid, Spain
    J Immunol 176:7143-7. 2006
    ..In the present study, we discuss the implications of epigenetic alterations in the development and progression of SLE and how epigenetic drugs constitute a promising source of therapy to treat this disease...
  60. ncbi A systematic profile of DNA methylation in human cancer cell lines
    Maria F Paz
    Cancer Epigenetics Laboratory, Molecular Pathology Program, Spanish National Cancer Center, Carlos III Institute of Health, 28029 Madrid, Spain
    Cancer Res 63:1114-21. 2003
    ..Our data provide a basis for a better use of human cancer cell lines in basic and translational research with respect to their DNA methylation environment...
  61. ncbi The transcription factor Slug represses E-cadherin expression and induces epithelial to mesenchymal transitions: a comparison with Snail and E47 repressors
    Victoria Bolós
    Instituto de Investigaciones Biomedicas Alberto Sols CSIC UAM, Arturo Duperier, 4, 28029 Madrid, Spain
    J Cell Sci 116:499-511. 2003
    ....
  62. ncbi High-performance capillary electrophoretic method for the quantification of 5-methyl 2'-deoxycytidine in genomic DNA: application to plant, animal and human cancer tissues
    Mario F Fraga
    Laboratorio de Fisiologia Vegetal, Dpt B O S, Facultad de Biologia, Universidad de Oviedo, Oviedo, Spain
    Electrophoresis 23:1677-81. 2002
    ....
  63. ncbi Distinctive gene expression of human lung adenocarcinomas carrying LKB1 mutations
    Paloma Fernandez
    Lymphomas and Lung Cancer Laboratory, Spanish National Cancer Centre CNIO, Madrid, Spain
    Oncogene 23:5084-91. 2004
    ....
  64. ncbi Genetic and epigenetic screening for gene alterations of the chromatin-remodeling factor, SMARCA4/BRG1, in lung tumors
    Pedro P Medina
    Lymphoma and Lung Cancer Group, Molecular Pathology Program Spanish National Cancer Centre CNIO, Madrid, Spain
    Genes Chromosomes Cancer 41:170-7. 2004
    ..We cannot rule out that other mechanisms, such as complete or partial deletions of the SMARCA4 gene, are contributing to the loss of the SMARCA4 protein in lung cancer...
  65. ncbi CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas
    Maria F Paz
    Cancer Epigenetics Laboratory, Spanish National Cancer Centre, Madrid, Spain
    Clin Cancer Res 10:4933-8. 2004
    ..Here, we investigate whether the presence of MGMT methylation in gliomas is also a good predictor of response to another emergent alkylating agent, temozolomide...
  66. ncbi CpG island promoter hypermethylation of the Ras-effector gene NORE1A occurs in the context of a wild-type K-ras in lung cancer
    Manuel Irimia
    Molecular Pathology Program, Cancer Epigenetics Laboratory, Spanish National Cancer Centre CNIO, Melchor Fernandez Almagro 3, Madrid 28029, Spain
    Oncogene 23:8695-9. 2004
    ..008, Fisher's exact test). Thus, the mutual exclusivity of the epigenetic and genetic alterations in the two genes of the Ras pathway suggests that they play a critical and cooperative role in human tumorigenesis...
  67. ncbi Abnormal PcG protein expression in Hodgkin's lymphoma. Relation with E2F6 and NFkappaB transcription factors
    Margarita Sanchez-Beato
    Molecular Pathology Programme, Centro Nacional de Investigaciones Oncologicas CNIO, C Melchor Fernandez Almagro 3, E 28029 Madrid, Spain
    J Pathol 204:528-37. 2004
    ..These results allow us to propose that the formation of transcription complexes with E2F6 may modify the functional status of PcG proteins in HSR cells...
  68. ncbi The impact of MECP2 mutations in the expression patterns of Rett syndrome patients
    Esteban Ballestar
    Cancer Epigenetics Laboratory, Molecular Pathology Programme, Spanish National Cancer Centre, Melchor Fernandez Almagro 3, 28029 Madrid, Spain
    Hum Genet 116:91-104. 2005
    ..Our results provide new data of the underlying mechanisms of RTT and unveil novel targets of MeCP2-mediated gene repression...
  69. ncbi A predictor based on the somatic genomic changes of the BRCA1/BRCA2 breast cancer tumors identifies the non-BRCA1/BRCA2 tumors with BRCA1 promoter hypermethylation
    Sara Alvarez
    Human Genetics Department, Molecular Pathology Programme, Spanish National Cancer Centre, c o Melchor Fernandez Almagro, 28029 Madrid, Spain
    Clin Cancer Res 11:1146-53. 2005
    ..This fact suggests that somatic BRCA1 inactivation could modify the profile of tumor progression in most of the BRCAX cases...
  70. ncbi EMP3, a myelin-related gene located in the critical 19q13.3 region, is epigenetically silenced and exhibits features of a candidate tumor suppressor in glioma and neuroblastoma
    Miguel Alaminos
    Cancer Epigenetics Laboratory, Molecular Pathology Programme, Spanish National Cancer Centre, Madrid, Spain
    Cancer Res 65:2565-71. 2005
    ..03) and death of disease (Kendall tau, P = 0.03; r = 0.19). Thus, EMP3 is a good candidate for being the long-sought tumor suppressor gene located at 19q13 in gliomas and neuroblastomas...
  71. pmc DNA methylation profiles and their relationship with cytogenetic status in adult acute myeloid leukemia
    Sara Alvarez
    Molecular Cytogenetics Group, Centro Nacional Investigaciones Oncologicas, Centro de Investigaciones de Enfermedades Raras, Madrid, Spain
    PLoS ONE 5:e12197. 2010
    ..However, further studies to discuss the prognostic value and the relationship of the epigenetic signatures with defined genomic rearrangements in acute myeloid leukemia are required...
  72. ncbi Loss of heterozygosity analysis at the BRCA loci in tumor samples from patients with familial breast cancer
    Ana Osorio
    Department of Human Genetics, Centro Nacional de Investigaciones Oncologicas, Madrid, Spain
    Int J Cancer 99:305-9. 2002
    ....
  73. ncbi Epigenetic and genetic alterations of APC and CDH1 genes in lobular breast cancer: relationships with abnormal E-cadherin and catenin expression and microsatellite instability
    David Sarrio
    Laboratory of Breast and Gynecological Cancer, Molecular Pathology Program, Centro Nacional de Investigaciones Oncologicas, Madrid, Spain
    Int J Cancer 106:208-15. 2003
    ..The same tumors also show genetic and epigenetic alterations of APC gene. However, altered CDH1 and APC genes do not promote beta-catenin accumulation in this tumor type...
  74. ncbi Inactivation of LKB1/STK11 is a common event in adenocarcinomas of the lung
    Montserrat Sanchez-Cespedes
    Department of Otolaryngology Head and Neck Surgery, Head and Neck Cancer Research Division, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205 2196, USA
    Cancer Res 62:3659-62. 2002
    ..Thus, our findings demonstrate for the first time that LKB1/STK11 inactivation is a very common event and may be integrally involved in the development of sporadic lung adenocarcinoma...
  75. pmc Identification of DNA hypermethylation of SOX9 in association with bladder cancer progression using CpG microarrays
    A Aleman
    Tumor Markers Group, Molecular Pathology Program, Spanish National Cancer Center, Madrid, Spain
    Br J Cancer 98:466-73. 2008
    ..The association of SOX9 hypermethylation with tumour progression and clinical outcome suggests its relevant clinical implications at stratifying patients affected with bladder cancer...
  76. pmc Genetic and epigenetic profile of sporadic pheochromocytomas
    A Cascon
    Hereditary Endocrine Cancer Group, Department of Human Genetics, Centro Nacional de Investigaciones Oncologicas, Madrid, Spain
    J Med Genet 41:e30. 2004
  77. ncbi Aberrant promoter methylation of the transcription factor genes PAX5 alpha and beta in human cancers
    William A Palmisano
    Lovelace Respiratory Research Institute, Lung Cancer Program, 2425 Ridgecrest Avenue S E, Albuquerque, New Mexico 87108, USA
    Cancer Res 63:4620-5. 2003
    ..Recent studies have demonstrated the importance of PAX5 gene alterations in human cancer. Our results are the first to identify aberrant promoter methylation as a common mechanism for dysregulation of these genes in solid tumors...
  78. ncbi The Polycomb group protein EZH2 directly controls DNA methylation
    Emmanuelle Viré
    Free University of Brussels, Faculty of Medicine, Laboratory of Molecular Virology, 808 Route de Lennik, 1070 Brussels, Belgium
    Nature 439:871-4. 2006
    ..Our results suggest that EZH2 serves as a recruitment platform for DNA methyltransferases, thus highlighting a previously unrecognized direct connection between two key epigenetic repression systems...
  79. ncbi Multiple markers for melanoma progression regulated by DNA methylation: insights from transcriptomic studies
    William M Gallagher
    Department of Pharmacology, University College Dublin, Ireland
    Carcinogenesis 26:1856-67. 2005
    ..Overall, our data support the hypothesis that multiple genes are targeted, either directly or indirectly, by DNA hypermethylation during melanoma progression...
  80. ncbi Aberrant promoter methylation of multiple genes throughout the clinico-pathologic spectrum of B-cell neoplasia
    Davide Rossi
    Hematology Unit, Dept of Medical Sciences and IRCAD, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy
    Haematologica 89:154-64. 2004
    ....
  81. ncbi Hypermethylation-associated Inactivation of the Cellular Retinol-Binding-Protein 1 Gene in Human Cancer
    Manel Esteller
    The Johns Hopkins Oncology Center, The Johns Hopkins Medical Institutions, Baltimore, Maryland 21231, USA
    Cancer Res 62:5902-5. 2002
    ..Epigenetic disruption of CRBP1 is a common event in human cancer that may have important implications for cancer prevention and treatment using retinoids...
  82. ncbi CHK2-decreased protein expression and infrequent genetic alterations mainly occur in aggressive types of non-Hodgkin lymphomas
    Frederic Tort
    Laboratory of Pathology, Hospital Clinic, Institut d Investigacions Biomediques August Pi i Sunyer IDIBAPS, University of Barcelona, Spain
    Blood 100:4602-8. 2002
    ..The high number of chromosomal imbalances in tumors with complete absence of CHK2 protein suggests a role of this gene in chromosomal instability in human lymphomas...
  83. ncbi SOCS-1, a negative regulator of cytokine signaling, is frequently silenced by methylation in multiple myeloma
    Oliver Galm
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231, USA
    Blood 101:2784-8. 2003
    ..Silencing of the SOCS-1 gene may impair negative regulation of the Jak/STAT pathway and therefore result in greater responsiveness to cytokines, thus supporting survival and expansion of MM cells...
  84. ncbi Chromatin remodeling factor CHD5 is silenced by promoter CpG island hypermethylation in human cancer
    Sonia Mulero-Navarro
    Cancer Epigenetics and Biology Program PEBC, Catalan Institute of Oncology ICO, Hospital Duran i Reynals, Barcelona, Catalonia, Spain
    Epigenetics 3:210-5. 2008
    ..These results underpin the epigenetic inactivation of the chromating remodeling factor CHD5 as one contributor for the aberrant structural changes of chromatin throughout the genome of the cancer cell...
  85. ncbi Hypermethylation of the DNA repair gene O(6)-methylguanine DNA methyltransferase and survival of patients with diffuse large B-cell lymphoma
    Manel Esteller
    Division of Cancer Biology, The Johns Hopkins Oncology Center, Baltimore, MD 21231, USA
    J Natl Cancer Inst 94:26-32. 2002
    ..MGMT promoter hypermethylation is a favorable prognostic marker in patients with brain tumors treated with alkylating agents...
  86. pmc GATA-4 and GATA-5 transcription factor genes and potential downstream antitumor target genes are epigenetically silenced in colorectal and gastric cancer
    Yoshimitsu Akiyama
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21231, USA
    Mol Cell Biol 23:8429-39. 2003
    ..Selection for silencing of both upstream transcription factors and their target genes in GI cancers could indicate that epigenetic silencing of the involved genes provides a summated contribution to tumor progression...
  87. ncbi Heterozygous disruption of Hic1 predisposes mice to a gender-dependent spectrum of malignant tumors
    Wen Yong Chen
    Division of Tumor Biology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Medical Institutions, 1650 Orleans Street, Baltimore, Maryland 21231, USA
    Nat Genet 33:197-202. 2003
    ..We conclude that HIC1 is a candidate tumor-suppressor gene for which loss of function in both mouse and human cancers is associated only with epigenetic modifications...
  88. doi Epigenetic biomarkers for human cancer: the time is now
    Sonia Mulero-Navarro
    Cancer Epigenetics and Biology Program PEBC, Catalan Institute of Oncology ICO, Hospital Duran i Reynals, Avinguda Gran Via s n Km 2 7, E 08907 L Hospitalet de Llobregat, Barcelona, Catalonia, Spain
    Crit Rev Oncol Hematol 68:1-11. 2008
    ....